Ovid Therapeutics (OVID) Assets Average (2017 - 2026)

Ovid Therapeutics has reported Assets Average for 10 years, with the latest figure at $188.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 116.64% year-over-year to $188.3 million; the trailing twelve-month figure through Mar 2026 stood at $188.3 million (up 116.64% YoY), and the FY2025 full-year result was $121.6 million, up 2.92% from the prior year.
• Assets Average for Q1 2026 stood at $188.3 million, up from $107.4 million in the prior quarter.
• The five-year high for Assets Average was $192.8 million in Q1 2022, with the low at $70.6 million in Q3 2025.
• Historically, Assets Average has averaged $133.3 million across 5 years, with a median of $134.5 million in 2023.
• Annual changes were most pronounced in 2025 — Assets Average slumped 36.94% — and 2026, when it jumped 116.64%.
• Ovid Therapeutics' Assets Average stood at $160.1 million in 2022, then retreated by 16.0% to $134.5 million in 2023, then decreased by 27.59% to $97.4 million in 2024, then gained by 10.25% to $107.4 million in 2025, then soared by 75.32% to $188.3 million in 2026.
• The last three Assets Average figures came in at $188.3 million (Q1 2026), $107.4 million (Q4 2025), and $70.6 million (Q3 2025), per Business Quant data.